These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 29465699

  • 1. Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study.
    Willows K, Bozat-Emre S, Righolt CH, Kliewer EV, Mahmud SM.
    Sex Transm Dis; 2018 Apr; 45(4):254-259. PubMed ID: 29465699
    [Abstract] [Full Text] [Related]

  • 2. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
    Righolt CH, Willows K, Kliewer EV, Mahmud SM.
    PLoS One; 2022 Apr; 17(4):e0267646. PubMed ID: 35472093
    [Abstract] [Full Text] [Related]

  • 3. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Nygård S, Nygård M, Orumaa M, Hansen BT.
    Vaccine; 2023 Aug 23; 41(37):5469-5476. PubMed ID: 37516572
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
    Righolt CH, Bozat-Emre S, Mahmud SM.
    Int J Cancer; 2019 Aug 01; 145(3):671-677. PubMed ID: 30653261
    [Abstract] [Full Text] [Related]

  • 5. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
    Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL.
    Vaccine; 2016 Sep 07; 34(39):4678-4683. PubMed ID: 27527815
    [Abstract] [Full Text] [Related]

  • 6. Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study.
    Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL.
    BMJ Open; 2016 Mar 10; 6(3):e009914. PubMed ID: 26966057
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
    Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA.
    J Clin Oncol; 2014 Feb 10; 32(5):438-43. PubMed ID: 24395857
    [Abstract] [Full Text] [Related]

  • 8. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
    Steben M, Ouhoummane N, Rodier C, Sinyavskaya L, Brassard P.
    J Med Virol; 2018 Mar 10; 90(3):592-598. PubMed ID: 28980715
    [Abstract] [Full Text] [Related]

  • 9. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
    Woestenberg PJ, Guevara Morel AE, Bogaards JA, Hooiveld M, Schurink-van 't Klooster TM, Hoebe CJPA, van der Sande MAB, van Benthem BHB.
    Clin Infect Dis; 2021 Jul 15; 73(2):291-297. PubMed ID: 32421775
    [Abstract] [Full Text] [Related]

  • 10. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.
    Smith LM, Strumpf EC, Kaufman JS, Lofters A, Schwandt M, Lévesque LE.
    Pediatrics; 2015 May 15; 135(5):e1131-40. PubMed ID: 25917991
    [Abstract] [Full Text] [Related]

  • 11. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
    Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, Arnheim-Dahlström L.
    J Natl Cancer Inst; 2013 Apr 03; 105(7):469-74. PubMed ID: 23486550
    [Abstract] [Full Text] [Related]

  • 12. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
    Dominiak-Felden G, Gobbo C, Simondon F.
    PLoS One; 2015 Apr 03; 10(7):e0132404. PubMed ID: 26147096
    [Abstract] [Full Text] [Related]

  • 13. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.
    Lamb F, Herweijer E, Ploner A, Uhnoo I, Sundström K, Sparén P, Arnheim-Dahlström L.
    BMJ Open; 2017 Jun 08; 7(6):e015021. PubMed ID: 28600369
    [Abstract] [Full Text] [Related]

  • 14. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, Arnheim-Dahlström L.
    JAMA; 2014 Feb 12; 311(6):597-603. PubMed ID: 24519299
    [Abstract] [Full Text] [Related]

  • 15. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity.
    Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M.
    Vaccine; 2020 Feb 05; 38(6):1345-1351. PubMed ID: 31917039
    [Abstract] [Full Text] [Related]

  • 16. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada.
    Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M.
    Sex Transm Dis; 2009 Jun 05; 36(6):380-6. PubMed ID: 19556932
    [Abstract] [Full Text] [Related]

  • 17. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada.
    Steben M, Tan Thompson M, Rodier C, Mallette N, Racovitan V, DeAngelis F, Stutz M, Rampakakis E.
    J Obstet Gynaecol Can; 2018 Dec 05; 40(12):1635-1645. PubMed ID: 30341021
    [Abstract] [Full Text] [Related]

  • 18. Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination.
    Tyros G, Mastraftsi S, Gregoriou S, Nicolaidou E.
    Int J STD AIDS; 2021 Jan 05; 32(1):4-13. PubMed ID: 33167803
    [Abstract] [Full Text] [Related]

  • 19. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
    Osmani V, Fett S, Tauscher M, Donnachie E, Schneider A, Klug SJ.
    BMC Cancer; 2022 Dec 09; 22(1):1293. PubMed ID: 36494790
    [Abstract] [Full Text] [Related]

  • 20. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH, Medical Microbiological Laboratories, Public Health Services.
    J Infect; 2017 Apr 09; 74(4):393-400. PubMed ID: 28126492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.